Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 14/20 | 0.38 |
| ▸ | CES2 | O00748 | 2/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.35 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 8/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25948178 | 1.00 | CES1 (0.38) | CES1CES2LPAR1LPAR3FAAH | |
| SCHEMBL9976286 | 1.00 | CES1 (0.38) | CES1CES2LPAR1LPAR3FAAH | |
| SCHEMBL493979 | 0.92 | CES2 (0.43) | CES1CES2LPAR1LPAR3 | |
| SCHEMBL21087422 | 0.90 | CES2 (0.47) | CES1CES2LPAR1LPAR3 | |
| SCHEMBL13684033 | 0.90 | CES2 (0.47) | CES1CES2LPAR1LPAR3 | |
| SCHEMBL11990032 | 0.83 | ALDH1A1 (0.35) | CES1 | |
| SCHEMBL11990036 | 0.83 | ALDH1A1 (0.35) | CES1 | |
| SCHEMBL92887 | 0.83 | ALDH1A1 (0.35) | CES1 | |
| SCHEMBL22624064 | 0.81 | CES1 (0.33) | CES1CES2LPAR1LPAR3FAAH | |
| SCHEMBL5857345 | 0.80 | ALDH1A1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4392432-A2 | POSITIVE NMDA-MODULATING COMPOUNDS AND METHODS OF USE THEREOF | Sage Therapeutics, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| WO-2023028278-A2 | POSITIVE NMDA-MODULATING COMPOUNDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | WO | disclosed |